Chemomab Therapeutics (CMMB) Assets (2017 - 2026)

Chemomab Therapeutics (CMMB) has reported Assets for 10 consecutive years, with $10.2 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Assets fell 8.01% year-over-year to $10.2 million; the trailing twelve-month figure through Jun 2026 stood at $10.2 million (down 8.01% YoY), and the FY2025 full-year result was $13.8 million, down 18.58% from the prior year.
• Assets slipped to $10.2 million in Q2 2026 per CMMB's latest filing, from $11.8 million in the prior quarter.
• Across five years, Assets topped out at $61.0 million in Q1 2022 and bottomed at $10.2 million in Q2 2026.
• Historically, Assets has averaged $25.7 million across 5 years, with a median of $19.5 million in 2024.
• The sharpest annual moves came in 2022 and 2023: Assets grew 1.39% in 2022, then plunged 53.37% in 2023.
• Over 5 years, Assets stood at $43.1 million in 2022, then plunged by 48.56% to $22.2 million in 2023, then decreased by 23.42% to $17.0 million in 2024, then decreased by 18.58% to $13.8 million in 2025, then retreated by 25.88% to $10.2 million in 2026.
• According to Business Quant data, Assets over the past three periods registered $10.2 million, $11.8 million, and $13.8 million for Q2 2026, Q1 2026, and Q4 2025 respectively.